MGTX
Meiragtx Holdings Plc Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$9.49Close
$769.8MMarket cap
$6.99 – $14.9752-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 40 · weaker than 60% of stocks over 12 months
- Far from its high 37% below its 52-week high
- Distribution down-day volume 1.8× up-day volume over 50 sessions
- Results soon Nov 12, 2026, in 11 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
37%
1wk
up 3.0%
price change
1mo
down 13.7%
price change
12-month return
up 9%
market up 11% ·
its own down 5%
F-score
—
— Not assessed
Altman Z
-4.08
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 14.1%
EBIT / enterprise value
Cheaper than
8%
of the market · expensive
Revenue growth
up 145%
year on year
EPS growth
—
latest quarter
Sales growth
up 8609%
latest quarter · +8693 pts
ROE
—
return on equity
Free cash margin
down 62%
-$50.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
Repair signals
- Long-term debt down 32% ($0.1B → $0.0B)
Trade setup
ATR%
5.6%
$0.53 a day · 2×ATR $8.44
RS
40 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.54
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$5.8M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 3.5% over the year, from 78m to 81m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 13, 2026
Results reaction
Aug 13, 2026+4% vs market2 sessions after results
Financials
- Net -140%
- Free cash -62%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $15.6M | $37.7M | $15.9M | $14.0M | $33.3M | $81.4M |
| Operating income | -$62.6M | -$72.8M | -$116.4M | -$137.1M | -$164.2M | -$106.0M |
| Net income | -$58.0M | -$79.6M | -$129.6M | -$84.0M | -$147.8M | -$114.2M |
| Net margin | -373% | -211% | -814% | -599% | -444% | -140% |
| Earnings per share | -$1.54 | -$1.80 | -$2.87 | -$1.49 | -$2.12 | -$1.42 |
| Free cash flow | -$84.9M | -$56.9M | -$118.1M | -$125.5M | -$109.5M | -$50.2M |
| Free cash margin | -545% | -151% | -742% | -896% | -329% | -62% |
| Cash | $209.5M | $137.7M | $115.5M | $129.6M | $103.7M | $65.9M |
| Long-term debt | — | — | $71.0M | $72.1M | $73.2M | $49.7M |
| Shareholders' equity | $238.6M | $185.4M | $117.7M | $138.2M | $67.8M | -$5.8M |
| Shares outstanding | 44.19m | 44.55m | 48.48m | 63.60m | 78.40m | 81.12m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 30, 2026 | Annual ↗ | Dec 31, 2025 | 89d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 13, 2025 | Annual ↗ | Dec 31, 2024 | 72d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 15, 2024 | Annual ↗ | Dec 31, 2023 | 75d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 23, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 13, 2026 | Results ↗ |
| Jul 7, 2026 | Material agreement · Agreement ended · New obligation · Unregistered share sale · Regulation FD ↗ |
| Jun 15, 2026 | Shareholder vote ↗ |
| May 14, 2026 | Results ↗ |
| Apr 24, 2026 | Material agreement ↗ |
| Apr 16, 2026 | Material agreement ↗ |
| Apr 16, 2026 | Material agreement · Agreement ended · Acquisition or disposal · Regulation FD · Other events ↗ |
| Apr 16, 2026 | Regulation FD · Other events ↗ |
| Mar 26, 2026 | Material agreement · Results · New obligation ↗ |
| Jan 2, 2026 | Material agreement ↗ |
| Nov 13, 2025 | Results ↗ |